Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Large Volume Increase

Centessa Pharmaceuticals plc (NASDAQ:CNTA) shares saw unusually-strong trading volume on Wednesday . Approximately 625,600 shares traded hands during mid-day trading, an increase of 78% from the previous session’s volume of 352,390 shares.The stock last traded at $9.02 and had previously closed at $9.40.

Analyst Upgrades and Downgrades

Separately, BMO Capital Markets reiterated an “outperform” rating and issued a $15.00 price objective on shares of Centessa Pharmaceuticals in a research report on Monday, April 1st. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Centessa Pharmaceuticals Stock Down 2.6 %

The stock has a 50-day simple moving average of $10.95 and a 200 day simple moving average of $8.50. The company has a quick ratio of 8.00, a current ratio of 8.00 and a debt-to-equity ratio of 0.32.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Thursday, March 28th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.06. The company had revenue of $6.85 million for the quarter. On average, equities research analysts forecast that Centessa Pharmaceuticals plc will post -1.83 EPS for the current year.

Insider Buying and Selling

In related news, insider Karen M. Anderson sold 51,160 shares of Centessa Pharmaceuticals stock in a transaction on Monday, March 25th. The stock was sold at an average price of $11.88, for a total transaction of $607,780.80. Following the completion of the sale, the insider now directly owns 71,525 shares of the company’s stock, valued at $849,717. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, insider Karen M. Anderson sold 51,160 shares of the business’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $11.88, for a total value of $607,780.80. Following the sale, the insider now directly owns 71,525 shares in the company, valued at $849,717. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Harris Rotman sold 4,267 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $8.10, for a total value of $34,562.70. Following the completion of the sale, the senior vice president now owns 62,625 shares in the company, valued at $507,262.50. The disclosure for this sale can be found here. 11.54% of the stock is owned by corporate insiders.

Institutional Trading of Centessa Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its holdings in Centessa Pharmaceuticals by 371.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock worth $51,000 after acquiring an additional 5,037 shares in the last quarter. Affinity Asset Advisors LLC lifted its position in Centessa Pharmaceuticals by 13.0% during the third quarter. Affinity Asset Advisors LLC now owns 1,018,091 shares of the company’s stock worth $6,587,000 after acquiring an additional 117,368 shares during the last quarter. Platinum Investment Management Ltd. boosted its holdings in shares of Centessa Pharmaceuticals by 96.7% during the third quarter. Platinum Investment Management Ltd. now owns 337,544 shares of the company’s stock worth $2,184,000 after acquiring an additional 165,919 shares during the period. Acuta Capital Partners LLC acquired a new position in shares of Centessa Pharmaceuticals in the third quarter valued at approximately $2,092,000. Finally, Adage Capital Partners GP L.L.C. increased its stake in shares of Centessa Pharmaceuticals by 25.8% during the third quarter. Adage Capital Partners GP L.L.C. now owns 2,830,500 shares of the company’s stock worth $18,313,000 after purchasing an additional 580,500 shares during the period. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.